| Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection |
72 |
| Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome |
63 |
| short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders |
52 |
| Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis |
40 |
| Market share and costs of biologic therapies for inflammatory bowel disease in the USA |
35 |
| An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease |
32 |
| Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications |
29 |
| Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions |
29 |
| The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis |
29 |
| Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies |
28 |
| Review article: systemic treatment of hepatocellular carcinoma |
28 |
| Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome |
27 |
| Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases |
27 |
| Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme |
27 |
| Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease |
26 |
| Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease |
25 |
| Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy |
25 |
| Review article: the gut microbiome in inflammatory bowel diseaseavenues for microbial management |
24 |
| Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt |
23 |
| Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection |
23 |
| Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study |
22 |
| Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis |
21 |
| Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry |
20 |
| Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation |
20 |
| Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study |
19 |
| Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentrereal- world cohort |
19 |
| Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 update |
19 |
| Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease |
19 |
| Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease |
18 |
| Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry |
18 |
| Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort |
18 |
| The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity |
18 |
| Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany |
17 |
| Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease |
17 |
| Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease |
17 |
| Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years |
17 |
| Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome |
17 |
| Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease |
17 |
| Population based study: atopy and autoimmune diseases are associated with functional dyspepsia and irritable bowel syndrome, independent of psychological distress |
17 |
| One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing |
17 |
| Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis |
17 |
| Systematic review: psychosocial factors associated with pain in inflammatory bowel disease |
16 |
| Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study |
16 |
| Review article: treatment options for functional dyspepsia |
16 |
| Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus |
16 |
| Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis |
16 |
| Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program |
16 |
| Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation |
16 |
| Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy |
15 |
| Review article: impact of exercise on physical frailty in patients with chronic liver disease |
15 |
